In an EDC study, user training and access must be monitored and addressed when all the following situations occur EXCEPT:
Answer(s): C
In Electronic Data Capture (EDC) studies, proper user training and access management are essential for maintaining data integrity, security, and regulatory compliance. According to the Good ClinicalData Management Practices (GCDMP) and FDA 21 CFR Part 11, EDC systems must ensure that only qualified and trained personnel can access study data, and that all access rights reflect current study responsibilities.User training and access must therefore be reviewed and updated whenever:Site staff leave the study (access revocation is required), New site staff are added (training and credentialing are required), and Study team members change roles (access levels must be modified accordingly). However, if a software upgrade occurs that does not impact the functional roles, user permissions, or data handling processes, retraining or reauthorization is not required. This is because such updates do not alter compliance-critical workflows or user interactions. Therefore, the exception is C when a software upgrade does not affect users.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture Systems, Section 7.1 User Access and Training Controls FDA 21 CFR Part 11 Electronic Records; Electronic Signatures, Section 11.10(i) & (k) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 System Security and User Training
A Clinical Data Manager reads a protocol for a clinical trial to test the efficacy of an antiviral to counteract a new epidemic. The stated primary efficacy endpoint is 3-month survival. Which data element is needed for the primary efficacy endpoint?
Answer(s): A
When the primary efficacy endpoint in a clinical trial is 3-month survival, the key data element required is the death date. This is because the survival endpoint is determined by calculating whether the subject lived or died within a defined time frame from study enrollment or randomization.According to the GCDMP (Chapter: Data Management Planning and Study Start-up), the Clinical Data Manager (CDM) must identify and ensure the capture of all critical data elements necessary to evaluate the study endpoints. For time-to-event analyses (e.g., survival studies), accurate event dates (death date) are essential for endpoint derivation and statistical analysis. Other data elements such as cause of death or date of autopsy (options B and C) may support secondary analyses or safety reviews but are not necessary to determine the survival endpoint itself. Similarly, birth date (option D) contributes to demographic data but is unrelated to the primary efficacy outcome.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning andStudy Start-up, Section 4.4 Critical Data Identification for Endpoints ICH E9 Statistical Principles for Clinical Trials, Section 2.2.3 Time-to-Event Data Considerations FDA Guidance for Industry: Clinical Trial Endpoints for Drug Development
Which method would best identify inaccuracies in safety data tables for an NDA?
Answer(s): B
The best method for identifying inaccuracies in safety data tables prepared for a New Drug Application (NDA) is to compare counts of appropriate patients from line listings of CRF data to the counts in table cells.According to the GCDMP (Chapter: Data Quality Assurance and Control), line listings represent raw, patient-level data extracted directly from the clinical database, whereas summary tables are aggregated outputs used for reporting and submission. Comparing these two sources ensures data traceability and accuracy, verifying that tabulated results correctly reflect the underlying patient data.Manual CRF checks (option A) are less efficient and error-prone, as data entry is typically already validated electronically. Simply reviewing tables or listings for "odd values" (options C and D) lacks the systematic verification necessary for regulatory data integrity. Thus, comparing line listings to tables (option B) provides a quantitative cross-check between the database and output deliverables, a standard practice in NDA data validation and statistical quality control.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 5.2 Validation of Tables, Listings, and Figures (TLFs)FDA Guidance for Industry: Submission of NDA Safety Data, Section on Data Verification and Accuracy ICH E6 (R2) GCP, Section 5.5.3 Validation of Derived Data Outputs
Which information is most useful in working with sites to catch up a backlog of unresolved queries at sites?
Answer(s): D
The most effective information for addressing a backlog of unresolved queries at investigative sites is a list of late queries by site combined with a summary table. According to the GCDMP (Chapter: Communication and Issue Escalation), timely and structured feedback to sites is critical for efficient query resolution. A detailed list of late or overdue queries, accompanied by summary statistics (e.g., counts, durations, status), enables data managers and monitors to prioritize follow-up actions, target problem areas, and provide focused support or retraining to underperforming sites.While query count summaries (option B) are helpful for overview metrics, they lack the specific information (query ID, date, field, status) required for targeted follow-up. Graphs of enrollment or clean cases (options A and C) are unrelated to discrepancy resolution performance. Thus, the combination of detailed lists and summarized performance metrics offers both granularity and a high-level overview -- the optimal tool for query management communication.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Communication and Issue Escalation, Section 5.1 Site Query Management Reports ICH E6 (R2) GCP, Section 5.18.4 Communication Between Monitors and Sites FDA Guidance for Industry: Oversight of Clinical Investigations Risk-Based Monitoring, Section on Query Metrics and Site Performance Review
The Medical Dictionary for Regulatory Activities (MedDRA) structure is in which of the following hierarchical orders, from most specific to least specific?
The MedDRA (Medical Dictionary for Regulatory Activities) is a standardized medical terminology used for coding and analyzing adverse event (AE) and medical history data in clinical trials. Its hierarchical structure supports aggregation, analysis, and reporting across varying levels of medical specificity.From most specific to least specific, the hierarchy is as follows:Lowest Level Term (LLT): The most granular term, often reflecting the verbatim text reported by the investigator.Preferred Term (PT): The standardized medical concept representing one or more LLTs describing the same condition.High Level Term (HLT): A grouping of related PTs describing similar medical conditions. High Level Group Term (HLGT): A broader grouping of related HLTs. System Organ Class (SOC): The highest level of classification, grouping HLGTs by body system or etiology (e.g., cardiac disorders, infections).Thus, the correct order -- from most specific to least specific -- is:LLT PT HLT HLGT SOC, which corresponds to option D.
(CCDM-Verified Sources)SCDM GCDMP, Chapter: Medical Coding and Dictionaries, Section 5.2 MedDRA Hierarchical StructureICH M1 MedDRA Terminology Guide, Version 26.0 Hierarchy Overview ICH E2B(R3) Guidelines Clinical Safety Data Management
Post your Comments and Discuss SCDM CCDM exam prep with other Community members:
Our website is free, but we have to fight against AI bots and content theft. We're sorry for the inconvenience caused by these security measures. You can access the rest of the CCDM content, but please register or login to continue.